Amicus Therapeutics
$14.43
41
+$0.05+0.35% Friday 20:00
Statistics
Day High
14.43
Day Low
14.37
52W High
14.43
52W Low
5.51
Volume
8,412,945
Avg. Volume
7,578,918
Mkt Cap
4.53B
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
13MayExpected
Expected EPS
0.03
Actual EPS
N/A
Financials
-4.27%Profit Margin
Unprofitable1.27BRevenue
-54.22MNet Income
Analyst Ratings
$14.67Average Price Target
The highest estimate is 19.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy 14%
Hold 86%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow FOLD. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Biogen
BIIB
Mkt Cap22.63B
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
Novartis
NVS
Mkt Cap237.61B
Pfizer
PFE
Mkt Cap140.15B
About
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Show more...
CEO
Mr. Bradley L. Campbell M.B.A.
Employees
499
Country
US
ISIN
US03152W1099
Listings
0 Comments
Share your thoughts
FAQ
What is Amicus Therapeutics stock price today?▼
The current price of FOLD is $14.43 USD — it has increased by +0.35% in the past 24 hours. Watch Amicus Therapeutics stock price performance more closely on the chart.
What is Amicus Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Amicus Therapeutics stocks are traded under the ticker FOLD.
Is Amicus Therapeutics stock price growing?▼
FOLD stock has risen by +0.42% compared to the previous week, the month change is a +0.49% rise, over the last year Amicus Therapeutics has showed a +60.24% increase.
What is Amicus Therapeutics market cap?▼
Today Amicus Therapeutics has the market capitalization of 4.53B
When is the next Amicus Therapeutics earnings date?▼
Amicus Therapeutics is going to release the next earnings report on May 13, 2026.
What were Amicus Therapeutics earnings last quarter?▼
FOLD earnings for the last quarter are 0.01 USD per share, whereas the estimation was 0.07 USD resulting in a -86% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Amicus Therapeutics revenue for the last year?▼
Amicus Therapeutics revenue for the last year amounts to 1.27B USD.
What is Amicus Therapeutics net income for the last year?▼
FOLD net income for the last year is -54.22M USD.
How many employees does Amicus Therapeutics have?▼
As of March 23, 2026, the company has 499 employees.
In which sector is Amicus Therapeutics located?▼
Amicus Therapeutics operates in the Health Care sector.
When did Amicus Therapeutics complete a stock split?▼
Amicus Therapeutics has not had any recent stock splits.
Where is Amicus Therapeutics headquartered?▼
Amicus Therapeutics is headquartered in Princeton, US.